Immunosequencing, the science of profiling T- and B-cell receptors, has broad utility across the clinical development spectrum. Adaptive Biotechnologies’ quantitative immunoSEQ® Technology can answer early, preclinical questions about drug candidate selection, dosing, and effective drug combinations. At the clinical trial stage, the immunoSEQ Assay can also help to confirm drug safety and efficacy, establish biomarker endpoints, optimize patient selection, predict responses to therapy, and monitor for adverse events. This webinar will use real-world data to demonstrate how immunosequencing can be used at various points in the drug development and clinical trial process to improve the development of new therapies for patients.

For Research Use Only. Not for use in diagnostic procedures.